Skip to main content
Premium Trial:

Request an Annual Quote

Zygem to Sell Rubicon Kits Down Under

NEW YORK (GenomeWeb News) – Zygem will market Rubicon Genomics' PicoPlex single-cell amplification kits in Australia and New Zealand, under a non-exclusive agreement, Rubicon said today.

Rubicon's kits are used to amplify small clinical samples into large amounts of pure DNA, and they are licensed and sold to clinical markets for pre-implantation and prenatal testing, cancer testing, and for making diagnostics.

DNA amplified using the PicoPlex can be analyzed using qPCR, microarrays, and next-generation sequencing technologies for either research or diagnostic purposes, and it represents genomic sequencings without the common problem of allele dropouts, Ann Arbor, Mich.-based Rubicon said.

Zygem makes DNA and RNA extraction and detection products and enzymes used in molecular biology and diagnostic applications. Its customers include those involved in basic research, forensics, clinical diagnostics, and agriculture.

"The PicoPlex technology nicely complements Zygem's advanced DNA extraction products and we are looking forward to bringing this cutting-edge technology to the markets we serve in Australia and New Zealand," Paul Kinnon, CEO of Zygem, said in a statement.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.